• 1
    Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104: 53143.
  • 2
    Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002; 51(Suppl. 1): S10916.
  • 3
    Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003; 92: 34J41J.
  • 4
    Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 4214.
  • 5
    Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep 2002; 4: 5964.
  • 6
    Desvergne B, Michalik L, Wahli W. Transcriptional regulation of metabolism. Physiol Rev 2006; 86: 465514.
  • 7
    Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 22017.
  • 8
    Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 116878.
  • 9
    Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 52750.
  • 10
    Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 51833.
  • 11
    Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005; 353: 60415.
  • 12
    Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001; 56: 23963.
  • 13
    DiRenzo J, Soderstrom M, Kurokawa R et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 1997; 17: 216676.
  • 14
    Chen J, Kinyamu HK, Archer TK. Changes in attitude, changes in latitude: nuclear receptors remodeling chromatin to regulate transcription. Mol Endocrinol 2006; 20: 113.
  • 15
    Yang W, Rachez C, Freedman LP. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 2000; 20: 800817.
  • 16
    Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24: 7890.
  • 17
    Zhang B, Berger J, Zhou G et al. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 1996; 271: 317714.
  • 18
    Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497505.
  • 19
    Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 64550.
  • 20
    Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993; 32: 5598604.
  • 21
    Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 131927.
  • 22
    Auwerx J, Schoonjans K, Fruchart JC, Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 1996; 3: 819.
  • 23
    Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord 2004; 5: 2559.
  • 24
    Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 184961.
  • 25
    Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001; 8: 18794.
  • 26
    Lee S, Gonzalez F. Targeted disruption of the peroxisome proliferator-activated receptor alpha gene, PPAR alpha. Ann N Y Acad Sci 1996; 804: 5249.
  • 27
    Aoyama T, Peters JM, Iritani N et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998; 273: 567884.
  • 28
    Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP. The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 33943.
  • 29
    Kersten S, Seydoux J, Peters J, Gonzalez F, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103: 148998.
  • 30
    Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP, Semenkovich CF. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 2003; 9: 106975.
  • 31
    Peters JM, Hennuyer N, Staels B et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997; 272: 2730712.
  • 32
    Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998; 273: 2957785.
  • 33
    Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 113.
  • 34
    Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 57180.
  • 35
    Staels B, Koenig W, Habib A et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 7903.
  • 36
    Marx N, Sukhova G, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 312531.
  • 37
    Marx N, Mackman N, Schonbeck U et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001; 103: 2139.
  • 38
    Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275: 367037.
  • 39
    Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 3943.
  • 40
    Zimetbaum P, Frishman WH, Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol 1991; 31: 2537.
  • 41
    Ziegler O, Drouin P. Safety, tolerability, and efficacy of simvastatin and fenofibrate–a multicenter study. Simvastatin-Fenofibrate Study Group. Cardiology 1990; 77(Suppl. 4): 507.
  • 42
    Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 4108.
  • 43
    Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003; 101: 54551.
  • 44
    Ye P, Li JJ, Su G, Zhang C. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. Clin Chim Acta 2005; 356: 22932.
  • 45
    Vohl MC, Lepage P, Gaudet D et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41: 94552.
  • 46
    Lacquemant C, Lepretre F, Pineda Torra I et al. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab 2000; 26: 393401.
  • 47
    Kanda H, Nohara R, Hasegawa K, Kishimoto C, Sasayama S. A nuclear complex containing PPARalpha/RXRalpha is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function. Heart Vessels 2000; 15: 1916.
  • 48
    Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H103743.
  • 49
    Finck BN, Han X, Courtois M et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003; 100: 122631.
  • 50
    Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, Roberts RA. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett 1999; 110: 11927.
  • 51
    Krey G, Braissant O, L’Horset F et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11: 77991.
  • 52
    Kliewer SA, Sundseth SS, Jones SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997; 94: 431823.
  • 53
    Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997; 94: 43127.
  • 54
    Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARalpha. Blood 2002; 100: 13406.
  • 55
    Brun RP, Tontonoz P, Forman BM et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996; 10: 97484.
  • 56
    Meirhaeghe A, Fajas L, Gouilleux F et al. A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 2003; 23: 28994.
  • 57
    Al-Shali K, Cao H, Knoers N, Hermus AR, Tack CJ, Hegele RA. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab 2004; 89: 565560.
  • 58
    Tontonoz P, Kim JB, Graves RA, Spiegelman BM. ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 1993; 13: 47539.
  • 59
    Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994; 91: 73559.
  • 60
    Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798800.
  • 61
    Mukherjee R, Jow L, Croston GE, Paterniti JR Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 80716.
  • 62
    Ricote M, Huang J, Fajas L et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95: 76149.
  • 63
    Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 1723.
  • 64
    Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097103.
  • 65
    Forman B, Tontonoz P, Chen J, Brun R, Spiegelman B, Evans R. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 80312.
  • 66
    Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep 2002; 4: 51421.
  • 67
    McIntyre TM, Pontsler AV, Silva AR et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 2003; 100: 1316.
  • 68
    Zhang C, Baker DL, Yasuda S et al. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med 2004; 199: 76374.
  • 69
    Schopfer FJ, Lin Y, Baker PR et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A 2005; 102: 23405.
  • 70
    Cui T, Schopfer FJ, Zhang J et al. Nitrated fatty acids: endogenous anti-inflammatory signaling mediators. J Biol Chem 2006; 281: 3568698.
  • 71
    Rossi A, Kapahi P, Natoli G et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403: 1038.
  • 72
    Davies SS, Pontsler AV, Marathe GK et al. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 2001; 276: 1601523.
  • 73
    Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 22940.
  • 74
    Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 35561.
  • 75
    Semple RK, Chatterjee VK, O’Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 5819.
  • 76
    Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004; 43: 297305.
  • 77
    Ye P, Fang H, Zhou X, He YL, Liu YX. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Chin Med Sci J 2004; 19: 2437.
  • 78
    Marx N, Mach F, Sauty A et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164: 65038.
  • 79
    Marx N, Kehrle B, Kohlhammer K et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 70310.
  • 80
    Liang CP, Han S, Okamoto H et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004; 113: 76473.
  • 81
    Chawla A, Boisvert WA, Lee CH et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 16171.
  • 82
    Chinetti G, Lestavel S, Bocher V et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 538.
  • 83
    Barak Y, Nelson MC, Ong ES et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 58595.
  • 84
    Kubota N, Terauchi Y, Miki H et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597609.
  • 85
    Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 4124554.
  • 86
    Babaev VR, Yancey PG, Ryzhov SV et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 164753.
  • 87
    Agarwal AK, Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 2006; 57: 297311.
  • 88
    Barroso I, Gurnell M, Crowley VE et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 8803.
  • 89
    Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: 122034.
  • 90
    Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 9539.
  • 91
    Hamer OW, Forstner D, Ottinger I et al. The Pro115Gln polymorphism within the PPAR gamma2 gene has no epidemiological impact on morbid obesity. Exp Clin Endocrinol Diabetes 2002; 110: 2304.
  • 92
    Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 2847.
  • 93
    Hara K, Okada T, Tobe K et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271: 2126.
  • 94
    Douglas JA, Erdos MR, Watanabe RM et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 2001; 50: 88690.
  • 95
    Ridker PM, Cook NR, Cheng S et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003; 23: 85963.
  • 96
    Mancini FP, Vaccaro O, Sabatino L et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999; 48: 14668.
  • 97
    Beamer BA, Yen CJ, Andersen RE et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 18068.
  • 98
    Evans D, De Heer J, Hagemann C et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 2001; 109: 1514.
  • 99
    Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000; 85: 20149.
  • 100
    Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142: 4195202.
  • 101
    Wang YX, Lee CH, Tiep S et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 15970.
  • 102
    Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 5907.
  • 103
    Johnson TE, Holloway MK, Vogel R et al. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. J Steroid Biochem Mol Biol 1997; 63: 18.
  • 104
    Muoio DM, MacLean PS, Lang DB et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 2002; 277: 2608997.
  • 105
    Cheng L, Ding G, Qin Q et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004; 10: 124550.
  • 106
    Wang YX, Zhang CL, Yu RT et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004; 2: e294.
  • 107
    Peters JM, Lee SS, Li W et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 511928.
  • 108
    Barak Y, Liao D, He W et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 2002; 99: 3038.
  • 109
    Chawla A, Lee CH, Barak Y et al. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A 2003; 100: 126873.
  • 110
    Lee CH, Chawla A, Urbiztondo N et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003; 302: 4537.
  • 111
    Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. Trends Endocrinol Metab 2002; 13: 1748.
  • 112
    Goldberg I. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693707.
  • 113
    Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002; 80: 75369.
  • 114
    Rip J, Nierman MC, Ross CJ et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006; 26: 123645.
  • 115
    Talmud PJ, Stephens JW. Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease risk. Diabetes Obes Metab 2004; 6: 17.
  • 116
    Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim Biophys Acta 1999; 1440: 13962.
  • 117
    Ziouzenkova O, Perrey S, Asatryan L et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 2003; 100: 27305.
  • 118
    Ziouzenkova O, Sevanian A. Oxidative modification of low-density lipoprotein (LDL) in HD patients: role in electronegative LDL formation. Blood Purif 2000; 18: 16976.
  • 119
    Ahmed W, Orasanu G, Nehra V et al. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 2006; 98: 4908.
  • 120
    Ziouzenkova O, Orasanu G, Sukhova G et al. Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol 2007; 21: 7788.
  • 121
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 245771.
  • 122
    Nathan DM. Rosiglitazone and Cardiotoxicity – Weighing the Evidence. N Engl J Med 2007 (in press).
  • 123
    Drazen JM, Morrissey S, Curfman GD. Rosiglitazone – Continued Uncertainty about Safety. N Engl J Med 2007 (in press).
  • 124
    Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. N Engl J Med 2007 (in press).
  • 125
    Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007 (in press).